B-type natriuretic peptide · Coronary artery disease · End-diastolic pressure · Hemodialysis · Heart failure · Cardiac troponin T Abstract Background: An increased cardiac troponin T (cTnT) level identifies a high-risk group in patients with end-stage renal disease; however, the mechanism of cTnT elevation remains unclear in such patients without acute coronary syndrome (ACS). Therefore, we explored the relationship between cTnT levels and the hemodynamic parameters and the prognostic potential of cTnT in stable patients with chronic hemodialysis (HD). Methods: We included consecutive 174 patients with HD who were referred for coronary angiography due to stable coronary artery disease (CAD), peripheral artery disease (PAD), or heart failure (HF). Hemodynamic measurement was performed, and plasma cTnT, B-type natriuretic peptide (BNP), and A-type natriuretic peptide (ANP) were measured at the same time. The potential of 3 biomarkers to predict all-cause mortality, cardiac death or hospitalized HF, and vascular event was assessed. Results: Increased log cTnT levels were correlated with increased log BNP and log ANP levels (r = 0.531, p < 0.001 and r = 0.411, p < 0.001, respectively). Not increased log cTnT, but increased log BNP and log ANP were associated with the presence of CAD and the extent of CAD. In contrast, they were all associated with the New York Heart Association functional classification and the presence of PAD and significantly correlated with left ventricular end-dia-stolic pressure (LVEDP) in an independent manner. Increased cTnT and BNP levels were associated with the mortality and hospitalized HF. However, increased cTnT was not associated with vascular events, unlike increased BNP. Conclusions: In patients with chronic HD without ACS, increased cTnT reflected increased LVEDP and the presence of HF or PAD independently, and it did not reflect the presence of CAD in contrast to increased BNP. cTnT and BNP were significant prognostic predictors; however, increased cTnT was associated with HF-related events, not with arteriosclerotic events. Of the total 174 patients, 63, 58, and 53 patients had non-CAD, single VD, and multiple VD, respectively. As shown in Figure 1a , plasma log BNP and log ANP levels increased progressively with the extent of CAD; however, there was no significant difference in log cTnT levels among the 3 groups. Furthermore, plasma log BNP and log ANP levels correlated positively with the Gensini score (r = 0.356, p < 0.001 and r = 0.286, p < 0.001, respectively), but log cTnT levels did not correlate with it (p = 0.246).
Introduction
Cardiovascular disease (CVD) is a leading cause of mortality in patients with hemodialysis (HD). Among them, up to 64% of patients with end-stage renal disease (ESRD) have evidence of chronic heart failure (HF) and chronic HF is responsible for high rates of mortality and morbidity in HD patients [1] . A high prevalence of atherosclerotic vascular events such as coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease is also observed in this population and highly associated with the mortality [2] . Recently, several cardiac biomarkers such as cardiac troponins (cTn), B-type natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-proBNP) have been demonstrated to be useful in profiling CVD risk and enabling stratification of early mortality in chronic kidney disease (CKD) including HD patients [3] . The biomarkers are utilized for early diagnosis and therapy for CVD including HF and atherosclerotic vascular events in the management of such patients [4] [5] [6] .
An elevation of cTn may be detected in conditions other than acute coronary syndrome (ACS), including HF, cardiomyopathies, myocarditis, tachyarrhythmia, and pulmonary embolism, and even after strenuous exercise in healthy individuals. In addition, levels of cTn are frequently elevated in the absence of ACS among patients with renal dysfunction, specifically in 30-75% of HD patients. More importantly, the test has prognostic value and has been reported that an increased cTn level identifies a high-risk group of HD patients [7, 8] . However, the mechanism of cTn increase in such patients remains unclear. In addition, several reports showed that cTn increase was associated with the prognosis independently of the elevation of natriuretic peptides (NPs) [4, 9] . Recently, we have suggested that left ventricular (LV) end-diastolic wall stress (EDWS) is a strong determinant of BNP in HF patients not only with normal renal function but also with CKD or HD [10] . We also have reported that plasma BNP levels showed a predictive value for CAD and were closely correlated with disease severity in HD patients [11] .
Therefore, to clarify the clinical significance of increased cardiac troponin T (cTnT) in patients with HD, we investigated the relationship of cTnT increase with hemodynamic parameters and the extent of CAD or HF in stable patients referred for coronary angiography (CAG) due to various CVDs. We also measured NPs such as BNP and A-type NP (ANP) and compared them with cTnT. Furthermore, we evaluated the prognostic potential of cTnT in detail and compared them with those of BNP and ANP. Lastly, since BNP was superior to ANP in the prognostic significance, we investigated the prognostic significance of cTnT in combination to BNP.
Methods

Study Protocol
This study was a single-centered study, where a cumulative total of 174 consecutive patients with HD referred for CAG were enrolled between February 2015 and November 2017 at the Nihon University Hospital. Among them, 39 patients underwent CAG repeatedly in the study period. The patients who had been referred for CAG due to CAD (symptoms, positive exercise electrocardiogram, or nuclear test), peripheral artery disease (PAD), or HF were enrolled in the present study. Patients with ACS including unstable angina and acute myocardial infarction were excluded from this study. All patients underwent regular 4-h sessions of HD using polysulfone membrane filters 3 times weekly. This study was approved by the Ethics Committee of Nihon University Hospital. The patients' informed consent was not required by local law because of the retrospective design of the study, and the patients whose informed consent was obtained in the form of opt-out on the website were excluded.
The blood sampling was obtained from the femoral or brachial artery at CAG. Highsensitive cTnT was measured using the EcLusys 2010 (Roche Diagnostics, Japan). The lower limit of detection is 0.003 ng/mL, while 99th percentile of the upper reference value for healthy subjects is 0.014 ng/mL [12] . Plasma BNP and ANP were measured by commercially available radioimmunoassay using Shiono RIA BNP and ANP (Shionogi Co, Ltd., Japan) with an intra-assay coefficient of variation of 5.3 or 5.8%, an interassay coefficient of variation of 5.9 or 11.9%, and lower detection limit of 2 or 5 pg/mL, respectively. These measurement systems are highly specific to BNP or ANP, with no cross-reactivity.
CAG and Lesion Morphology
CAG was performed following a standard technique. Two experienced cardiologists who were blinded to cTnT or plasma NP levels assessed the coronary angiograms. Quantitative CAG was performed using Centricity Cardiology CA1000 (GE Healthcare, USA) by an independent experienced physician. Diameter stenosis of ≥70% by quantitative angiography was accepted as significant. Extent of CAD was classified as 1-, 2-, or 3-vessel disease (VD) by the standard method. The Gensini score is a measure of the extent and severity of CAD and is computed by assigning a severity score to each coronary segment according to the degree of luminal narrowing and its geographic importance [13] . LV pressure was obtained with a 4-French or 5-French diagnostic catheter (Judkins Right 4 or left and right dual-purpose catheter) connected to a fluid-filled transducer.
Echocardiography
Echocardiographic examinations were performed using EPIQ 7C (Philips, The Netherlands) within a few days around CAG. M-mode images were obtained to measure left atrial and LV dimensions [14] . The LV mass index was estimated using the formula of Devereux. In patients with sinus rhythm, the pulsed Doppler transmitral flow velocity was recorded to measure the ratio of peak mitral E-wave velocity to peak mitral A-wave velocity (E/A ratio) and the deceleration time of the mitral E-wave velocity. Tissue Doppler early diastolic mitral annular velocity (E′) from the septal was recorded, and the ratio of E-wave velocity to E′-wave velocity (E/E′) was then calculated. End-diastolic volume and end-systolic volume were derived from the LV volume curve. Ejection fraction (EF) was calculated by modified Simpson's method. Based on hemodynamic and echocardiographic data, EDWS was calculated as follows: EDWS = 0.334 × EDP(LVEDD)/WT(1 + WT/LVEDD), where EDP = end-diastolic pressure, which was obtained during cardiac catheterization), LVEDD = LV end-diastolic dimension, and WT = wall thickness [15] Clinical Follow-Up The long-term clinical follow-up, through December 2018 from TnT/NPs testing, was accomplished in a total of 135 patients after excluding the duplicates through a questionnaire completed by the patient, telephone interview, or a chart review. The primary end point was an all-cause death. The secondary end points were cardiac death or hospitalized HF and vascular event. The vascular event was defined as ACS, percutaneous coronary intervention (PCI), coronary artery bypass grafting, percutaneous peripheral intervention, and amputation for PAD, stroke, or aortic aneurysm operation. All events were based on the clinical diagnosis; however, to validate these events, the medical records were reviewed by us or the physician in charge.
Statistical Analysis
Groups were compared using a chi-square analysis for proportions and unpaired student t tests or ANOVA/Kruskal-Wallis test for continuous variables. The linearity of a relationship between the 2 variables was assessed by linear regression analysis. Spearman and Pearson correlation coefficients were used to assess correlations between the 2 continuous variables. Further, multivariable regression analysis was performed to evaluate the independent relationship between hemodynamic index and the 3 biomarkers in concert with the presence of CAD, PAD, and HF (i.e., New York Heart Association [NYHA] functional classification ≥II) using JMP version 13. For covariates in hemodynamic index, the parameter with the strongest univariate correlation, that is, left-ventricle end-diastolic pressure (LVEDP) was included in the multivariate model. Event-free survival curves were analyzed using the Kaplan-Meier method, and a comparison between the curves was carried out using the log-rank test. Cox's proportional hazard model analysis was performed to confirm the independency of cTnT and BNP for the prediction of mortality after adjustment for age and gender. Hazard ratios (HRs) and 95% CIs were calculated. p < 0.05 was considered significant. Results were expressed as mean ± SD.
Results
Patient Characteristics
The baseline clinical characteristics according to the presence of CAD or NYHA functional classification are shown in Table 1 . In all of the studied patients, the mean age was 67.6 ± 11.6 years and 24% of the patients were female. Increased cTnT, BNP, and ANP levels (above normal ranges) were observed in all patients. Patients with CAD were more likely to have a history of hypertension, myocardial infarction, PCI, and coronary artery bypass grafting and be taking statin and β blocker. Log BNP and ANP levels were significantly increased in CAD group, and there were no significant differences in other cardiac biomarkers and laboratory data between CAD and non-CAD groups. Patients with NYHA ≥II were more likely to have lower body mass index and a history of myocardial infarction, PCI, and aortic disease compared with those with NYHA I. They showed increases of log cTnT, log BNP level, and log ANP levels and a decrease of serum albumin level.
The echocardiographic and hemodynamic findings according to the presence of CAD or NYHA functional classification are shown in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000502232). There was no significant difference in the echocardiographic and hemodynamic parameters except LVEDD, LVMI, and EF between non-CAD and CAD groups. In the patients with NYHA ≥II, increased LVEDD, LV end-diastolic volume, LVMI, E/A, E/E', LVEDP, and EDWS and decreased EF were observed compared with those with NYHA I.
Correlations between cTnT, Plasma BNP and ANP Levels (online suppl. Fig.1 ) Log cTnT levels were well correlated with plasma log BNP and log ANP levels (r = 0.531, 0.411, p < 0.001, respectively). Furthermore, the correlation of plasma log BNP levels with plasma log ANP levels was more robust (r = 0.819, p < 0.001). Values are mean ± SD, median (interquartile range), or n (%). ACEI, angiotensin-converting enzyme inhibitor; ANP, A-type natriuretic peptide; ARB, angiotensin receptor blocker; AF, atrial fibrillation; BMI, body mass index; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CAG, coronary angiography; CGN, chronic glomerulonephritis; CRP, C-reactive protein; cTnT, cardiac troponin T; DM, diabetes mellitus; HF, heart failure; HLP, hyperlipidemia; HT, hypertension; NYHA, New York Heart Association functional classification; OMI, old myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PCKD, polycystic kidney disease. We divided the patients into 3 groups according to the NYHA functional classification: NYHA I (n = 131), NYHA II (n = 31), and NYHA ≥III (n = 12). There was a significant difference in log cTnT among the NYHA groups as shown in Figure 1b . Plasma log BNP and log ANP levels also increased progressively with the severity of NYHA classification.
In PAD patients, log cTnT levels as well as log BNP and log ANP levels were significantly increased (Fig. 1c) .
Correlation of cTnT Levels to Hemodynamic Parameters in Comparison to Plasma BNP and ANP Levels
Log cTnT and plasma log BNP and log ANP levels were all correlated with LVEDP (r = 0.491, 0.503, 0.378, p < 0.001, respectively) as shown in Figure 2a . Log cTnT was also correlated with LV EDWS (r = 0.404, p < 0.001), but the relationship was not superior to that in LVEDP. Although plasma log BNP and log ANP levels were significantly correlated with LVMI and LV EF (LVMI; r = 0.350, 0.306, p < 0.001, LV EF; r = 0.400, r = 0.310, p < 0.001), log cTnT levels were significantly, but, weakly, correlated with LVMI and LV EF (r = 0.207, p = 0.009, and 0.246, p = 0.002, respectively) as shown in Figure 2b and c.
Multivariate Linear Regression Analysis of the Determinants for the Cardiac Biomarkers (Table 2)
Multivariate linear regression analysis revealed that LVEDP remained independently and positively associated with log cTnT after adjustment for the presence of CAD, NYHA clas- Table 2 ). The fit (R 2 ) of the model was 0.295. Furthermore, it was independently and positively predictive for plasma log BNP and log ANP levels. The fit (R 2 ) of the model was 0.492 and 0.249, respectively.
The Survival Analysis of Biomarkers
During a median follow-up of 733 days, a total of 22 (16%) patients experienced all-cause death, including 13 events related to HF, 3 sudden cardiac deaths, 3 infections, and 3 others. Thirty-nine vascular events included 23 ACS and coronary revascularizations, 13 percutaneous peripheral intervention and amputations for PAD, and 3 aortic and cerebrovascular events. According to median values of cTnT, BNP, and ANP levels, the population was divided into 2 groups: cTnT ≥0.066 and < 0.066 ng/mL, BNP ≥224 and < 224 pg/mL, and ANP ≥189 and < 189 pg/mL. Kaplan-Meier curves demonstrated that a group with higher cTnT, BNP, or ANP level had worse all-cause mortality and cardiac death/hospitalized HF compared with that with lower level of the biomarkers (Fig. 3a, b ). However, higher cTnT was not associated with the incidence of vascular events compared with lower cTnT, unlike higher ANP and BNP groups (Fig. 3c) . To determine the potential utility of simultaneous cTnT and BNP assessment, the patients were divided into 4 groups based on cTnT and BNP median values. Patients with elevated levels of both cTnT and BNP had an increased risk for mortality and cardiac death or hospitalized HF (Fig. 4) . Both cTnT and BNP levels in patients with the events (all-cause mortality and cardiac death or hospitalized HF) were significantly higher than patients without the events (online suppl. Table 2 ). Interestingly, cTnT levels in patients with the vascular events were not increased compared with patients without the vascular events, but BNP levels were increased in patients with the vascular events. Among the baseline characteristics, lower body mass index and higher log C-reactive protein level were associated with the mortality in addition to the 3 biomarkers (online suppl. Table 3 ). In multivariate Cox proportional hazard analysis, higher cTnT and higher BNP groups were independently associated with all-cause mortality after adjustment for age and gender (p = 0.034, HR 2.80, 95% CI 1.08-8.69 and p < 0.001, HR 6.16, 95% CI 2.00-26.97, respectively).
Discussion
This is a first report, to the best of our knowledge, to measure LVEDP and cardiac biomarkers simultaneously in dialysis patients with stable CVD. In patients with chronic HD without ACS, increased cTnT reflected increased LVEDP and the presence of HF or PAD independently, and it did not reflect the presence of CAD in contrast to increased BNP. cTnT and BNP were significant prognostic predictors; however, increased cTnT was associated with HF-related events, not with arteriosclerotic events. These results suggest that cTnT may be an important and useful marker for hemodynamics and HF-related events in chronic HD patients.
Numerous cardiac biomarkers have been evaluated and useful to predict mortality in HD patients [3, 16, 17] . In particular, many clinical studies on cTns and NPs have been reported; however, there have been few studies exploring the mechanisms underlying the cTns release and NPs elevation, probably due to the many confounding factors in HD patients. Several studies have explored the mechanism of cTn elevation in HF patients, but they were all in those without severe renal dysfunction. Horwich et al. [18] showed the association between cTnI and impaired hemodynamics or the progression of LV dysfunction in 238 patients with advanced HF. Recently, Takashio et al. [19] have shown that the difference in cTnT levels between coronary sinus and aortic root correlated with LVEDP or pulmonary capillary wedge pressure in stable 76 HF patients. The association between cTnT and LVEDP in 167 patients with chronic stable HF was also reported by Shionimya et al. [20] . These are similar to the present findings, where the patients with stable CAD, HF, and CAD were all on regular HD. LVEDP was strongly correlated with all 3 biomarkers examined (cTnT, plasma ANP, and BNP), but cTnT was not strongly correlated with the indices of cardiac systolic function and hypertrophy compared with plasma ANP and BNP. The exact mechanism in the association remains unclear; however, high LV filling pressure (preload increase) may cause myocyte injury by endomyocardial ischemia or increased cardiac wall stress may release cTnT independent of cardiac ischemia or necrosis. The basic research using swine model by Weil et al. [21] supports the latter mechanism. In the present study, cTnT was not associated with CAD, presumably with ischemia. In HD patients, increase or change of LV preload condition are frequently observed, and it may be associated with baseline increase of cTnT.
The increased wall stress is also suggested as one of the mechanisms underlying increased NPs in HF. Previous studies including ours showed that diastolic wall stress was strongly and independently associated with the increased NPs in a broad spectrum of HF patients with or without renal dysfunction [10, 15] . The common factors may explain the close association between cTnT and NPs, which has been observed not only in the present study but also in other studies [22] . Plasma BNP levels were elevated with increasing severity of HF evaluated based on NYHA classification [23] . cTnT was also reported to be increased with the extent of NYHA in patients with hypertrophic cardiomyopathy [24] and aortic stenosis [24] . Similarly, the 3 biomarkers were all increasing in proportion to the severity of NYHA classification in the present study. Furthermore, the association between NYHA classification and increased cTnT, BNP, and ANP, independent of the hemodynamic load and CAD according to the multivariable analysis, may suggest that they are all better clinical markers for HF even in HD patients. Hs-troponin assays have a decisive role for diagnosis and risk stratification in patients with ACS. Many clinical researches showed that high-sensitive cTnT levels increased and correlated with the angiographic atherosclerotic extent and burden in stable CAD patients with normal kidney function [25] . Recently, in HD patients with stable CAD, we have shown that plasma BNP levels were closely associated with the severity as assessed by the number of stenotic coronary arteries, the Gensini score, and CAD prognostic index [11] . The present study in a different cohort of HD patients showed that plasma ANP and BNP levels were associated with the presence and severity of CAD, which is consistent with our previous study; however surprisingly, cTnT levels were not increased compared to patients without CAD and not correlated with the severity of CAD. The reason for the contradictory result remains unclear. Chamberlain et al. suggested that, although cTnT levels were associated with angiographic CAD in patients with normal kidney function, the association was very weak in patients with CKD and ESRD [26] . The relationship between CAD and cTnT might disappear in the case of renal dysfunction. In contrast, deFilippi et al. [27] found that, even in stable patients undergoing long-term HD, a high level (>median) versus a low level of cTnT remained an independent predictor of multivessel disease (prevalence ratio, 3.7-fold) after adjustment for age and history of clinical CAD. Further studies are necessary for elucidating clinical roles of cTns in patients with stable CAD and HD.
Hs-cTn levels are often increased in CKD patients without clinical ACS or HF [28, 29] , and it is more frequently elevated in patients with ESRD [7, 30] . Consistent with many clinical studies, the present study has shown that cTnT was elevated in all HD patients with CVD and that it was observed even in patients with NYHA classification I and no CAD. However, the pathophysiologic mechanisms causing random increases in cTn concentrations in patients with CKD or dialysis are unclear. cTn elevation in HD patients is unlikely to be the result of decreased clearance by the failing kidney [31] . In addition, clinical significance of increased cTn concentrations in CKD patients with HF as well as those with stable CAD is unclear. Chen et al. [32] reported the association of an elevated cTnI with HF in 293 non-ACS patients with CKD, where stage 5 CKD did not modify it. A recent research by Michos and colleagues have shown the association of elevated cTns with worse prognosis in CKD patients (receiving or not receiving dialysis) without suspected ACS in a systematic review of 98 studies [33] . Considering the present results that LVEDP was a strong predictor of increased cTnT, cTn elevation might represent a stressed heart or reflect ongoing cardiac damage in nonischemic cardiomyopathy or microvascular disease in the setting of LV hypertrophy.
We analyzed the prognostic implication of cTnT compared to NPs with respect to all-cause mortality and the incidence of cardiac events including cardiac deaths, hospitalized HF, and vascular events in patients with HD. Several large studies have shown both cTns and BNP/ NT-proBNP to be strong predictors of cardiac events in HD patients [4, 5, 9, 16, 28] . However, some conflicting results have been reported, and one of the remaining problems is what pathophysiology cTns and NPs may reflect in this clinical situation, respectively. Bargnoux et al. [34] suggested that BNP and C-reactive protein were independent predictors of mortality but not TnI. Satyan et al. [5] reported in 150 HD patients without symptoms that NT-proBNP was strongly related with all-cause mortality and CV mortality, but the combination of troponin did not improve the prognostic value compared with NT-proBNP alone. In contrast, Apple et al. [4] have suggested that both cTnT and cTnI were independent predictors of all-cause mortality unlike NT-proBNP. Our results showed a robust association between cTnT and all-cause mortality and cardiac death or hospitalized HF as well as BNP in HD patients without ACS. However, cTnT was not related to vascular events unlike ANP and BNP. That may be because baseline cTnT levels did not show any relationships with the presence and extent of CAD, which was highly associated with the future vascular events (data not shown). cTnT may be a prognostic biomarker without reflecting CAD or ischemia in stable HD patients. Although BNP was more relevant to HF, CAD and PAD, and prognosis than cTnT, cTnT and BNP were independently associated with all-cause mortality. cTnT might be a prognostic marker for any events other than HF or vascular events. Further studies are necessary to clarify it.
The present study was a single-center study and thus has inherent limitations, including selection and referral biases. The study population was relatively small and any negative findings could thus be caused by a low statistical power. Also, the measurements of LVEDP and the biomarkers were performed at the day between HD session, and the echocardiography was performed at the different day. The timing of biomarkers' measurement and the time lag could have influenced the results.
In conclusion, both increased cTnT and BNP reflected increased LVEDP and the presence of HF independently in patients with chronic HD without ACS. However, increased cTnT did not reflect the presence of CAD in contrast to increased BNP. cTnT and BNP were significant prognostic predictors; however, increased cTnT was associated with HF-related events, not with arteriosclerotic events.
